# US 2026/0076900 A1 · Ipratropium delivery compositions, devices and methods

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2026/0076900 A1
- Document ID: US20260076900A1
- Status: Published application
- Kind: A1
- Application number: 19/328,020
- Filed: 2025-09-12
- Published: 2026-03-19
- Earliest claimed: 2024-09-16
- Assignees: Solstice Advanced Materials US, Inc.
- Applicants: Solstice Advanced Materials US, Inc.
- Inventors: Erik Boldt; Gregory Laurence Smith
- Web page: https://patentgrep.com/patent/US20260076900A1

## CPC

- A61K 9/008: {comprising drug dissolved or suspended in liquid propellant for inhalation via a pressurized metered dose inhaler [MDI]}
- A61K 31/439: the ring forming part of a bridged ring system, e.g. quinuclidine (8-azabicyclo [3.2.1] octanes A61K31/46)
- A61K 47/10: Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
- A61K 47/12: Carboxylic acids; Salts or anhydrides thereof
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)

## Abstract

Disclosed are medicinal compositions, and devices, methods and systems which provide ipratropium bromide carried by at least 1234ze(E) and ethanol.

## Claims

### Claim 1

A pressurized metered dose inhaler (pMDI) comprising:
a. a container;
b. a pharmaceutical formulation under pressure in the container, said pharmaceutical formulation comprising: (i) about from about 75% by weight to about 95% by weight of HFO-1234ze(E); (ii) from about 5% by weight to about 25% by weight of ethanol; and (iii) ipratropium bromide in solution in said ethanol and/or said HFO-1234ze; and
c. a normally closed valve on the container
d. an actuator fluidly connected to the valve and having an orifice diameter of less than 0.5 mm, said valve being actuatable to an open position to release said pharmaceutical formulation to pass through said orifice and produce an aerosol spray containing ipratropium bromide in solution.

### Claim 2 (depends on 1)

The pMDI of claim 1 wherein said pharmaceutical composition further comprises from greater than 0.005% by weight to less than 0.015% by weight of a stabilizer and from 0.1% by weight to about 1.5% by weight of water.

### Claim 3 (depends on 2)

The pMDI of claim 2 wherein said stabilizer comprises citric acid.

### Claim 4 (depends on 1)

The pMDI of claim 1 wherein said actuator orifice has a diameter of from greater than 0.1 mm to less than 0.45 mm.

### Claim 5 (depends on 1)

The pMDI of claim 1 wherein said actuator orifice has a diameter of from greater than 0.15 mm to less than 0.4 mm.

### Claim 6 (depends on 1)

The pMDI of claim 1 wherein said actuator orifice has a diameter of from greater than 0.15 mm to less than 0.35 mm.

### Claim 7 (depends on 2)

The pMDI of claim 2 wherein said pharmaceutical formulation comprises: (i) about from about 80% by weight to about 87% by weight of HFO-1234ze(E); (ii) from about 12% by weight to about 20% by weight of ethanol; and (iii) ipratropium bromide in solution in said ethanol and/or said HFO-1234ze and/or said water.

### Claim 8 (depends on 2)

The pMDI of claim 2 wherein said pharmaceutical formulation comprises: (i) about from about 85% by weight to about 95% by weight of HFO-1234ze(E); (ii) from about 5% by weight to about 15% by weight of ethanol; and (iii) ipratropium bromide in solution in said ethanol and/or said HFO-1234ze and/or said water.

### Claim 9 (depends on 8)

The pMDI of claim 8 wherein said actuator orifice has a diameter of from greater than 0.15 mm to less than 0.35 mm.

### Claim 10

A method of delivering a dose of ipratropium bromide to the respiratory tract of an animal comprising:
a. providing in a pMDI comprising:
i. a canister;
ii. a formulation comprising ipratropium bromide in solution contained in the canister, said formulation comprising: (1) from about 75% by weight to about 88% by weight of HFO-1234ze(E); (2) from about 13% by weight to about 25% by weight of ethanol; and (3) ipratropium bromide; and
iii. a metering valve releasably closing the canister and having orifice diameter of less than 0.5 mm; and
b. actuating said pMDI to produce an aerosol spray of said ipratropium bromide.

### Claim 11 (depends on 10)

The method of claim 10 wherein said actuating of said pMDI comprises actuating said pMDI to produce said aerosol spray and wherein said aerosol spray has a fine particle fraction of greater than about 40%.

### Claim 12 (depends on 10)

The method of claim 10 wherein said actuating of said pMDI comprises actuating said pMDI to produce said aerosol spray and wherein said aerosol spray has a fine particle fraction of greater than about 45%.

### Claim 13 (depends on 12)

The method of claim 12 wherein said actuator orifice has a diameter of from greater than 0.15 mm to less than 0.35 mm.

### Claim 14 (depends on 10)

The method of claim 10 wherein said pharmaceutical formulation comprises: (i) about from about 80% by weight to about 87% by weight of HFO-1234ze(E); (ii) from about 13% by weight to about 18% by weight of ethanol; and (iii) ipratropium bromide in solution in said ethanol and/or said HFO-1234ze.

### Claim 15 (depends on 10)

The method of claim 10 wherein said pharmaceutical formulation comprises: (i) about from about 82% by weight to about 87% by weight of HFO-1234ze(E); (ii) from about 13% by weight to about 18% by weight of ethanol; and (iii) ipratropium bromide in solution in said ethanol and/or said HFO-1234ze.

### Claim 16 (depends on 10)

The method of claim 10 wherein said pharmaceutical formulation comprises: (i) about from about 83% by weight to about 86% by weight of HFO-1234ze(E); (ii) from about 14% by weight to about 17% by weight of ethanol; and (iii) ipratropium bromide in solution in said ethanol and/or said HFO-1234ze.

### Claim 17 (depends on 10)

The method of claim 10 wherein said pharmaceutical formulation comprises: (i) about from about 84% by weight to about 86% by weight of HFO-1234ze(E); (ii) from about 14% by weight to about 16% by weight of ethanol; and (iii) ipratropium bromide in solution in said ethanol and/or said HFO-1234ze.

### Claim 18 (depends on 10)

The method of claim 10 wherein said pharmaceutical formulation comprises: (i) about 84% by weight of HFO-1234ze(E); (ii) about 16% by weight of ethanol; and (iii) ipratropium bromide in solution in said ethanol and/or said HFO-1234ze.

### Claim 19

A pharmaceutical composition in the form of an aerosol spray comprising particles comprising ipratropium bromide and wherein greater than about 40% by weight of said spray of particles are particles having a size of 5 microns or less.

### Claim 20 (depends on 9)

The pharmaceutical composition of claim 9 wherein greater than about 45% by weight of said spray of particles are particles having a size of 5 microns or less.
